Literature DB >> 17388570

Solution structure of a designed spirocyclic helical ligand binding at a two-base bulge site in DNA.

Na Zhang1, Yiqing Lin, Ziwei Xiao, Graham B Jones, Irving H Goldberg.   

Abstract

The solution structure of the complex formed between an oligodeoxynucleotide containing a two-base bulge (5'-CCATCGTCTACCTTTGGTAGGATGG) and SCA-alpha2, a designed spirocyclic helical molecule, has been elucidated. SCA-alpha2, a close mimic of the metabolite, NCSi-gb, of the DNA bulge-specific enediyne antibiotic neocarzinostatin, differs in possessing a more stable spirocyclic ring system and in lacking certain bulky groupings that compromise bulged DNA binding. This study provides a detailed comparison of the binding modes of the two complexes and provides new insights into the importance of shape and space, as opposed to simple nucleotide sequence, in complex formation at the bulge site. The two rigidly held aromatic rings of SCA-alpha2 form a right-handed helical molecular wedge that specifically penetrates the bulge-binding pocket and immobilizes the two bulge residues (GT), which point toward the minor groove, rather than the major groove as in the NCSi-gb.bulged DNA complex. The ligand aromatic ring systems stack on the DNA bulge-flanking base pairs that define the long sides of the triangular prism binding pocket. Like NCSi-gb, SCA-alpha2 possesses the natural N-methylfuranose moiety, alpha-linked to the benzindanol (BI) moiety. The amino sugar anchors in the major groove of the DNA and points toward the 3'-bulge-flanking base pair. Lacking the bulky cyclocarbonate of NCSi-gb, the SCA-alpha2.bulged DNA complex has a much less twisted and buckled 3'-bulge-flanking base pair (dG20.dC8), and the G20 residue stacks directly above the BI ring platform. Also, the absence of the methyl group and the free rotation of the methoxy group on the dihydronaphthanone (NA) moiety of SCA-alpha2 allow better stacking geometry of the NA ring above the 5'-bulge-flanking dG21.dC5 base pair. These and other considerations help to explain why NCSi-gb binds very poorly to bulged RNA and are consistent with the recent observation of good binding with SCA-alpha2. Thus, although the two complexes resemble each other closely, they differ in important local environmental details. SCA-alpha2 has a better hand-in-glove fit at the bulge site, making it an ideal platform for the placement of moieties that can react covalently with the DNA and for generating congeners specific for bulges in RNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388570      PMCID: PMC2569200          DOI: 10.1021/bi602599d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Analysis of the binding of p53 to DNAs containing mismatched and bulged bases.

Authors:  N Degtyareva; D Subramanian; J D Griffith
Journal:  J Biol Chem       Date:  2000-12-20       Impact factor: 5.157

2.  Molecular probes of DNA bulges: functional assay and spectroscopic analysis.

Authors:  Graham B Jones; Yiqing Lin; Ziwei Xiao; Lizzy Kappen; Irving H Goldberg
Journal:  Bioorg Med Chem       Date:  2006-10-26       Impact factor: 3.641

3.  Spirocyclic helical compounds as binding agents for bulged RNA, including HIV-2 TAR.

Authors:  Ziwei Xiao; Na Zhang; Yiqing Lin; Graham B Jones; Irving H Goldberg
Journal:  Chem Commun (Camb)       Date:  2006-09-14       Impact factor: 6.222

4.  Probing DNA bulges with designed helical spirocyclic molecules.

Authors:  Lizzy S Kappen; Yiqing Lin; Graham B Jones; Irving H Goldberg
Journal:  Biochemistry       Date:  2007-01-16       Impact factor: 3.162

5.  Solution structure of a two-base DNA bulge complexed with an enediyne cleaving analog.

Authors:  A Stassinopoulos; J Ji; X Gao; I H Goldberg
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

6.  Probing the structure of long single-stranded DNA fragments with neocarzinostatin chromophore. Extension of the base-catalyzed bulge-specific reaction.

Authors:  A Stassinopoulos; I H Goldberg
Journal:  Biochemistry       Date:  1995-11-21       Impact factor: 3.162

7.  Mechanistic studies on the base-catalyzed transformation of neocarzinostatin chromophore: roles of bulged DNA.

Authors:  Z Xi; Q K Mao; I H Goldberg
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

8.  The recognition of distorted DNA structures by HMG-D: a footprinting and molecular modelling study.

Authors:  D Payet; A Hillisch; N Lowe; S Diekmann; A Travers
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

9.  Methylation of cytosine at C5 in a CpG sequence context causes a conformational switch of a benzo[a]pyrene diol epoxide-N2-guanine adduct in DNA from a minor groove alignment to intercalation with base displacement.

Authors:  Na Zhang; Chin Lin; Xuanwei Huang; Aleksandr Kolbanovskiy; Brian E Hingerty; Shantu Amin; Suse Broyde; Nicholas E Geacintov; Dinshaw J Patel
Journal:  J Mol Biol       Date:  2004-12-31       Impact factor: 5.469

10.  Convenient synthesis of NCS-chromophore metabolite isosteres: binding agents for bulged DNA microenvironments.

Authors:  Yiqing Lin; Graham B Jones; Geum-Sook Hwang; Lizzy Kappen; Irving H Goldberg
Journal:  Org Lett       Date:  2005-01-06       Impact factor: 6.005

View more
  3 in total

Review 1.  Structure-based DNA-targeting strategies with small molecule ligands for drug discovery.

Authors:  Jia Sheng; Jianhua Gan; Zhen Huang
Journal:  Med Res Rev       Date:  2013-04-30       Impact factor: 12.944

2.  Designed DNA probes from the neocarzinostatin family: impact of glycosyl linkage stereochemistry on bulge base binding.

Authors:  Dong Ma; Yiqing Lin; Ziwei Xiao; Lizzy Kappen; Irving H Goldberg; Amy E Kallmerten; Graham B Jones
Journal:  Bioorg Med Chem       Date:  2009-02-10       Impact factor: 3.641

3.  Structure-guided post-SELEX optimization of an ochratoxin A aptamer.

Authors:  Guohua Xu; Jiajing Zhao; Na Liu; Minghui Yang; Qiang Zhao; Conggang Li; Maili Liu
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.